MarketCap
Facebook
X
Telegram
Chembio Diagnostics Operating Income | CEMI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.6 M | -31.1 M | -23.1 M | -13.3 M | -7.98 M | -6.48 M | -7.57 M | -3.55 M | -1.55 M | 1 M | 1.45 M | 1.09 M | 2.57 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 M | -31.1 M | -8.63 M |
Quarterly Operating Income Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -5.99 M | -6.22 M | -8.05 M | - | -5.63 M | -8.34 M | -3.86 M | - | -4.91 M | -7.27 M | -4.42 M | - | -3.61 M | -3.3 M | -3.1 M | - | -2.33 M | -1.75 M | -654 K | - | -589 K | -2.18 M | -1.63 M | - | -2.14 M | -2.39 M | -468 K | - | -579 K | -898 K | -875 K | - | -262 K | -233 K | -383 K | - | 1.07 M | -380 K | 487 K | - | -485 K | 512 K | 720 K | - | 479 K | 197 M | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 197 M | -8.34 M | 3.26 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.48 B | $ 171.29 | 2.09 % | $ 48.6 B |  USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.95 | 6.5 % | $ 95.7 K | USA |
 |
Biodesix
BDSX
|
-27.9 M | $ 29.06 | 4.83 % | $ 219 M | USA |
 |
Biomerica
BMRA
|
-5.32 M | $ 2.05 | 0.84 % | $ 5.98 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.45 | 0.96 % | $ 7.9 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-54.8 M | $ 15.83 | 0.62 % | $ 166 M |  China |
 |
Bioventus
BVS
|
54 M | $ 13.52 | 2.97 % | $ 901 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 69.85 | 4.02 % | $ 3.72 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 73.62 | 2.11 % | $ 3.44 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 310.77 | 7.07 % | $ 15.4 B | USA |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 36.65 | 3.07 % | $ 1.06 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 232.22 | 0.07 % | $ 25.8 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 221.21 | 3.34 % | $ 158 B | USA |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 5.8 | 1.24 % | $ 23.1 M |  Israel |
 |
DexCom
DXCM
|
912 M | $ 86.9 | 1.8 % | $ 33.9 B | USA |
 |
Fulgent Genetics
FLGT
|
-91.1 M | $ 22.45 | 4.52 % | $ 691 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 187.22 | 5.3 % | $ 23.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
443 M | $ 168.33 | 3.88 % | $ 13.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 527.07 | 1.67 % | $ 42.4 B | USA |
 |
Illumina
ILMN
|
807 M | $ 293.69 | 7.56 % | $ 45.5 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 266.09 | 3.05 % | $ 45.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 308.65 | 0.05 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 100.19 | 0.23 % | $ 6.76 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 620.51 | 3.51 % | $ 17.9 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.58 | 0.88 % | $ 424 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 6.31 | 4.13 % | $ 4.97 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 19.13 | 3.57 % | $ 2.45 B | USA |
 |
Neogen Corporation
NEOG
|
-21.6 M | $ 13.01 | 7.08 % | $ 2.83 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 20.78 | 2.11 % | $ 465 M | USA |
 |
Natera
NTRA
|
-310 M | $ 425.64 | 3.73 % | $ 58.2 B | USA |
 |
OPKO Health
OPK
|
-117 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 2.87 | 12.99 % | $ 861 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 23.91 | 0.04 % | $ 22.7 B |  Niderland |
 |
Precipio
PRPO
|
-1.2 M | $ 24.0 | 3.76 % | $ 38.5 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 16.4 | 0.74 % | $ 1.46 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | $ 45.79 | 2.34 % | $ 9.95 B | Niderland |
 |
RadNet
RDNT
|
62 M | $ 70.63 | 1.0 % | $ 5.31 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 10.31 | 4.35 % | $ 430 M | USA |
 |
Sotera Health Company
SHC
|
298 M | $ 18.55 | 1.81 % | $ 5.27 B | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 2.2 | 1.85 % | $ 145 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 676.76 | 3.35 % | $ 255 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 205.0 | 8.66 % | $ 12.3 B | USA |
 |
VolitionRx Limited
VNRX
|
-21.7 M | $ 0.23 | 0.35 % | $ 28.9 M |  Singapore |
 |
Waters Corporation
WAT
|
271 M | $ 440.12 | 3.51 % | $ 26.2 B | USA |
 |
Exagen
XGN
|
-14.1 M | $ 8.46 | 3.55 % | $ 182 M | USA |
 |
Syneos Health
SYNH
|
403 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |